실로시빈은 기억상실성 경도 인지 장애에서 시냅스 밀도를 변화시키는가?
실로시빈은 기억상실성 경도 인지 장애 환자의 뇌에서 시냅스 밀도를 변화시키는가?
The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brain will be higher following the ingestion of psilocybin in comparison to placebo, and that increases in SVD will be associated with improvements in cognition.
10 participants (6 with aMCI, and 4 sex and age matched healthy volunteers) will:
-
Be randomized to receive either:
- Two 25 mg macrodoses of psilocybin separated by 1 week.
- Two placebo doses separated by 1 week.
-
Receive a baseline 18F-SynVesT-1 PET scan, clinical, and neuropsychological assessments.
-
Receive a 18F-SynVesT-1 PET scan one week after the last dose of treatment.
-
Depending on available funds, receive a third PET scan at any time within 4 weeks of the screening visit to quantify tauopathy with the [18F]T807 radiotracer.
-
Receive clinical and neuropsychological testing 1, 4, and 12 weeks after the last treatment.
Researchers will compare placebo vs. experimental groups to see if psilocybin will increase SVD, and if increases in SVD are associated with cognitive improvements.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The proposed study will investigate the effects of on synaptic vesicular density (SVD) levels as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, and cognition (i.e., global cognition, executive function, and memory domains) in amnestic Mild Cognitive Impairment (aMCI) and healthy participants. Participants will be randomized to receive either two 25mg doses of psilocybin separated by one week, or two placebo doses separated by one week. Brain scans, clinical, and cognitive assessments will be conducted one week before, and one week, four weeks, and 12 weeks post dosing.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5T 1R8
- Centre for Addiction and Mental Health
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
The aMCI participant must meet all of the inclusion criteria to be eligible for this clinical trial:
- Male or female participants of any race or ethnicity
- Inpatients or outpatients 60 to 75 years of age (on day of randomization)
- Diagnosis of MCI based on DSM 5 diagnostic criteria of Minor Neurocognitive Disorder
- Categorization of episodic memory impairment based on scores ≥ 1.0 SD lower on any of the following measures in comparison to normative data i. Logical Memory Test, ii. California Verbal Learning Test, iii. Brief Visual Memory Test
- Non-smoker/Non-nicotine user
- Montreal Cognitive Assessment (MoCA) score = < 26 and MMSE score > = 24
- Capable of consenting to participate in the research study
- On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
- Availability of a study partner who has regular contact with the participant
- Ability to read and communicate in English (with corrected vision and hearing, if needed)
The Healthy Control participant must meet all of the inclusion criteria to be eligible for this clinical trial:
- Male or female participants of any race or ethnicity
- 60 to 75 years of age (on day of randomization)
- Does not meet SCID-5 criteria for Mild Neurocognitive Disorder, Alzheimer's disease, or other major neurocognitive disorder
- Non-smoker/Non-nicotine user
- Capable of consenting to participate in the research study
- On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
- Availability of a study partner who has regular contact with the participant
- Ability to read and communicate in English (with corrected vision and hearing, if needed)
Exclusion Criteria
An individual who meets any of the following criteria will be excluded from participation in this clinical trial:
- Unwilling or incapable to consent to the study
- Unstable medical or any concomitant major medical or neurological illness, including presence of a relative or absolute contraindication to psilocybin, i.e. a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment.
- History of head trauma resulting in loss of consciousness > 30 minutes that required medical attention.
- DSM-5 diagnosis, with active symptoms in the last three months, of major depression; lifetime diagnosis of bipolar disorder; intellectual disability; Alzheimer's Disease; or a psychotic disorder
- DSM-5 substance dependence (except caffeine) within 12 months of entering the study
- Anticonvulsant, antidepressant, antipsychotic, mood stabilizer, opioid, or benzodiazepine use
- Use of serotonergic psychedelic drugs within the past 10 years
- Positive urine drug screen at the screening visit
- Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks
- Acute suicidal or homicidal ideation
- Receiving treatment with medications such as levetiracetam that blocks SV2a binding, and/or inability to discontinue the following medications before study drug dosing: inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT)1A9 and (UGT)1A10, and ALDH inhibitors and alcohol dehydrogenase (ADH) inhibitors.
- Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines
- Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)
- Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia)
- Female with childbearing potential*, pregnancy (as confirmed by a negative pregnancy test) or breastfeeding
- Active gender affirming hormonal treatment
- Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I or II disorder as determined by the family medical history form and discussions with the participant.
- Allergies to hydroxypropyl methylcellulose *A woman/female or person who is not of childbearing potential is considered to be postmenopausal after at least 12 months without menstruation. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Females/people of childbearing potential are those who have experienced menarche and do not meet the criteria for women not of childbearing potential.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Amnestic Mild Cognitive Impairment Participants Receiving Psilocybin
Receiving 2 doses of 25mg of psilocybin separated by 1 week. |
2 macrodoses of 25mg separated by one week. |
|
실험적: Healthy Participants Receiving Psilocybin
Receiving 2 doses of 25mg of psilocybin separated by 1 week. |
2 macrodoses of 25mg separated by one week. |
|
위약 비교기: Amnestic Mild Cognitive Impairment Participants Receiving Placebo
Receiving 2 doses of placebo separated by 1 week. |
2 doses of placebo separated by one week. |
|
위약 비교기: Healthy Participants Receiving Placebo
Receiving 2 doses of placebo separated by 1 week. |
2 doses of placebo separated by one week. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Synaptic Vesicular Density
기간: 3 years
|
Synaptic vesicular density will be assessed with PET imaging by measuring the volume of distribution (i.e., defined as the ratio of the radioligand concentration in tissue target region (CT, kBq·cm-3) to that in plasma (CP, kBq·mL-1) at equilibrium) of the [18F]SynVesT-1 radioligand in the cortical and subcortical gray matter regions in the whole brain and more specifically, the hippocampus and dorsolateral prefrontal cortex. |
3 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Global Cognition
기간: 3 years
|
The results of the neuropsychological battery will be combined to a global cognition composite score as a Z-score, the change of which will be a secondary outcome measure. Z-scores will be comprised of the Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure, and will be calculated based on the performance of the equated comparison group. Each domain will contribute equally to the global cognition composite score. |
3 years
|
|
Memory
기간: 3 years
|
A memory composite Z-score will be generated using the performance on the following individual tests: Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score. |
3 years
|
|
Executive Function
기간: 3 years
|
An executive function composite Z-score will be generated using the performance on the following individual tests: Trail Making Test Part B, Wisconsin Card Sorting Test, Stroop Neuropsychological Screening, and the Executive Interview. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score. |
3 years
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Exploratory Cognitive Outcomes
기간: 3 years
|
If individual cognitive test scores are significantly different between groups, the mean difference of the individual test scores (i.e., Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure) will be analyzed separately as exploratory outcomes. |
3 years
|
|
Exploratory Primary and Secondary Outcomes
기간: 3 years
|
Primary and secondary outcomes will be compared between aMCI and healthy control groups. The means of the primary outcome (i.e., volume of distribution) and secondary outcomes (i.e., cognitive composite Z-scores: global cognition, memory, and executive function) will be compared between aMCI and healthy control groups. |
3 years
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Philip Gerretsen, MD, PhD, Centre for Addiction and Mental Health
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 101-2021
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .